Background: India is facing a heavy burden of non-communicable diseases (NCDs) due to explosion in the epidemiological transition worldwide. In that mainly cardiometabolic risk factors like dyslipidemia play an important role in the prevalence of NCDs. According to the National Obesity Forum in Nottingham, UK, obesity itself can be the fundamental cause of numerous other illnesses and conditions, including cardiovascular disease, hypertension, stroke, hyperlipidemia, diabetes, cancers, osteoarthritis, respiratory disorders, sleep apnea, fertility problems, Alzheimer’s disease, depression, and other psychological disorders. Obesity has not historically been categorized as a disease; therefore, treatment options covered by health insurance plans have been limited. A combination of genetics, lifestyle behaviors, and comorbidities represents the lion’s share of determinants.
Aims and Objectives: The effect of Kalonji (Nigella sativa) seed oil on lipid profile is seen on cardiometabolic risk factors partly, that is, dyslipidemia in high-fat diet-induced hyperlipidemic albino rats.
Materials and Methods: After obtaining approval from the Animal Ethics Committee, the albino rats of weighing 120–200 g were selected and induced hyperlipidemia by giving high-fat diet for 4 weeks. The basal lipid profiles were estimated and also hyperlipidemic levels were estimated after 4 weeks of high-fat diet. Then, oral feeding started with the standard drug atorvastatin 10 mg and with extract of Kalonji seed oil of low dose 200 mg and 600 mg/kg body weight of high dose is given for a period of 1 month. Again lipid profile estimation was done on days 14 and 30. The data analyzed statistically analyzed by drawing mean and standard deviation.
Results: It is observed that a high dose 600 mg/kg body weight of Kalonji showed significant hypolipidemic activity as compared to a low dose 200 mg/kg. It lowers total cholesterol and low-density lipoprotein levels significantly as that of the standard drug atorvastatin 10 mg/kg.
Conclusion: Kalonji (N. sativa) has produced hypolipidemic activity significantly with a high dose 600 mg/kg significantly as that of atorvastatin 10 mg/kg. Kalonji also has not produced any toxic changes like hepatotoxicity at high doses. Hence, Kalonji as anti-dyslipidemic proves in decreasing the risk factors in the development of NCDs.
Key words: Atorvastatin; Cardiovascular Disease; Dyslipidemia; Hypolipidemia; Kalonji; Non-Communicable Diseases; Nigella sativa
|
